A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs TAK 114 (Primary)
- Indications Prostate cancer; Systemic lupus erythematosus; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Takeda
- 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 11 Nov 2014 New trial record